Browse the evidence

Semaglutide, tirzepatide, and retatrutide achieve placebo-subtracted bodyweight loss of up to 10.8%, 17.8%, and 22.1%, respectively, in adults after 48-72 weeks.

These medications can significantly aid in weight loss for adults with obesity.

Semaglutide reduces body mass index mean by up to 16.7% in adolescents with obesity after 68 weeks.

Semaglutide can be effective for weight management in adolescents with obesity.

Tirzepatide likely results in a greater percentage reduction in body weight from baseline (mean difference -16.03, 95% CI -18.91 to -13.14) compared to placebo.

Practitioners can consider tirzepatide as an effective option for weight loss in adults with obesity.

Tirzepatide likely increases the number of people achieving a 5% weight reduction (risk ratio 3.60, 95% CI 2.44 to 5.30) compared to placebo.

Tirzepatide may be particularly effective for helping patients achieve significant weight loss goals.

Retatrutide administered at a 12 mg dosage resulted in significant reductions in body weight, body mass index, and waist circumference.

Practitioners can consider retatrutide as an effective treatment option for obesity.

A higher percentage of patients receiving retatrutide achieved weight losses of ≥5%, 10%, 15%, and 20% compared to placebo.

Retatrutide may be particularly effective for patients aiming for significant weight loss.

Retatrutide treatment for 48 weeks resulted in a least-squares mean percentage change in body weight of -24.2% in the 12 mg group compared to -2.1% in the placebo group.

Retatrutide may be an effective treatment option for significant weight loss in adults with obesity.

A weight reduction of 5% or more occurred in 100% of participants who received 8 mg of retatrutide.

The 8 mg dose of retatrutide is highly effective for achieving at least a 5% weight loss in this population.

A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group compared to 22.4% in the placebo group.

Semaglutide may help reduce liver fibrosis in patients with MASH.

In the 10-mg tirzepatide group, 56% of participants achieved resolution of MASH without worsening of fibrosis compared to 10% in the placebo group (difference of 46 percentage points; P<0.001).

Tirzepatide may be an effective treatment option for patients with MASH and moderate to severe fibrosis.

In the 5-mg tirzepatide group, 44% of participants achieved resolution of MASH without worsening of fibrosis compared to 10% in the placebo group (difference of 34 percentage points; P<0.001).

Tirzepatide may be an effective treatment option for patients with MASH and moderate to severe fibrosis.

Semaglutide treatment led to a mean change in the WOMAC pain score of -41.7 points compared to -27.5 points with placebo (P<0.001).

Semaglutide may significantly reduce pain in obese individuals with knee osteoarthritis.

Participants in the semaglutide group had a greater improvement in SF-36 physical-function score (mean change, 12.0 points) compared to the placebo group (mean change, 6.5 points; P<0.001).

Semaglutide may improve physical function in obese individuals with knee osteoarthritis.

The mean weight loss after 3 months of semaglutide treatment was 6.7 kg, equivalent to 5.9%.

Practitioners can expect significant weight loss in patients treated with semaglutide over 3 months.

The mean weight loss after 6 months of semaglutide treatment was 12.3 kg, equivalent to 10.9%.

Practitioners can expect continued weight loss in patients treated with semaglutide over 6 months.

87.3% of patients achieved weight loss of 5% or more after 6 months.

Practitioners can expect a high proportion of patients to achieve at least 5% weight loss with semaglutide.

Liraglutide, 3.0 mg, leads to a mean percentage body weight reduction of -8.82% compared to -0.54% with placebo over 24 weeks.

Liraglutide can be considered as an effective adjunct therapy for weight management in patients struggling after metabolic surgery.

Semaglutide 2.4 mg once weekly significantly reduces body weight by approximately 15%, with simultaneous improvement in cardiometabolic risk factors and physical functioning in people with obesity.

Practitioners can consider semaglutide as an effective treatment option for weight loss in obese patients.

Tirzepatide has recently demonstrated that body weight reduction exceeding 20% in people with obesity is feasible.

Tirzepatide may be considered for patients seeking substantial weight loss.

In adults with obesity, GLP-1 receptor agonists demonstrate 15% to 20% weight loss.

GLP-1 receptor agonists can be considered effective for weight management in obese adults.

Tirzepatide (15 mg once weekly) resulted in weight loss of up to 17.8% after 72 weeks of therapy.

Tirzepatide is an effective option for weight loss in adults without diabetes.

Semaglutide (2.4 mg once weekly) resulted in weight loss of up to 13.9% after 68 weeks.

Semaglutide is a viable weight loss treatment for adults without diabetes.

GLP-1 receptor agonists and co-agonists are efficacious for weight loss with safety concerns predominantly gastrointestinal.

Practitioners should consider GLP-1 RAs for weight management, noting gastrointestinal side effects.

Semaglutide 2.4 mg weekly significantly reduces Major Adverse Cardiovascular Events (MACE) in obese patients without type 2 diabetes, independent of the magnitude of weight loss.

If you have obesity (BMI ≥ 27) but no diabetes, weekly semaglutide (2.4 mg) is a proven therapy to significantly lower your risk of heart attack, stroke, and cardiovascular death. This benefit happens through direct protection of your blood vessels and reduction of inflammation, not just by making you lose weight. To get the best results, you must pair the medication with a gradual dose increase to minimize stomach issues, and you must actively engage in resistance training and eat enough protein to prevent muscle loss.